PCM
PACB icon

Peregrine Capital Management’s Pacific Biosciences PACB Stock Holding History

Peregrine Capital Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-974,505
Closed -$8.73M – 259
2016
Q3 		$8.73M Buy
+974,505
New +$8.15M 0.23% 205

Other funds holding PACB

MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $39B AUM 18.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Peregrine Capital Management's PACB Position: Q4 2016 in Review

Peregrine Capital Management sold out of Pacific Biosciences (PACB) in Q4 2016, closing a stake of 974,505 shares — an estimated $8.73M sold.

Peregrine Capital Management first reported a position in PACB in Q3 2016 and held it in 1 quarter. The position peaked at $8.73M in Q3 2016. 115 funds tracked by Wall St. Rank hold PACB as of Q4 2016.

  • Peregrine Capital Management reported no remaining Pacific Biosciences position as of Q4 2016 after selling out during the quarter.
  • Peregrine Capital Management sold 974,505 Pacific Biosciences shares in Q4 2016, an estimated $8.73M.
  • Peregrine Capital Management first reported a position in Pacific Biosciences in Q3 2016 and held it in 1 quarter.
  • Peregrine Capital Management's Pacific Biosciences position peaked at $8.73M in Q3 2016.
  • 115 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2016.

Based on Peregrine Capital Management's 13F filing for Q4 2016, filed 9 Feb 2017.